iSCIB1+ MHRA CTA Approval for Ph3 trial

Summary by AI BETAClose X

Scancell Holdings plc has received UK MHRA Clinical Trial Authorization for its Phase 3 registrational trial of iSCIB1+ in advanced melanoma, a significant step following FDA IND clearance. This global trial aims to enroll 550 patients across 90 sites, with initial progression-free survival data anticipated in the second half of 2028. The trial design is informed by Phase 2 results showing a 77% progression-free survival at 22 months and 87.4% overall survival at 18 months when iSCIB1+ was combined with ipilimumab and nivolumab. The company expects the trial to commence by the end of 2026.

Disclaimer*

UK 100

Latest directors dealings